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Abstract We examined the promoter activity of two homo-
logous plasminogen-related genes (PRGA and PRGB) employing 
HepG2 cells. The 5'-flanking regions of these genes were 
sequenced first, then inserted into the upstream region of the 
CAT gene in an expression vector. CAT assays revealed that the 
promoter activity of PRGA was 3-fold that of plasminogen, while 
the activity of PRGB was 5-fold. Deletion analysis of these genes 
demonstrated that a region between —283 and +153 bp relative 
to the transcription initiation site was essential for their 
expression, and that there were regions with either negative or 
positive effects on expression farther upstream. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Plasminogen (PLG) is a key proenzyme of plasmin in the 
fibrinolytic and thrombolytic systems. Cleavage at the Arg5 6 1-
Val562 bond in P L G by tissue P L G activator or urokinase 
results in the formation of a serine protease plasmin. Plasmin 
also appears to play an important role in processes which 
involve the breakdown of extracellular matrices, such as tu-
mor cell migration, angiogenesis, and neurodevelopment 
[1-3]. 
Two genes highly homologous to P L G were found and 
designated PLG-related genes A (PRGA) and B (PRGB). 
These genes belong to the PLG-apolipoprotein (a) gene family 
[4,5]. The gene products of P R G A and P R G B are expected to 
be polypeptides of 8.8 k D a that correspond only to the pre-
activation peptide domain of P L G . This domain plays an 
essential role in conversion of the 'activation-resistant' con-
formation of native P L G to its 'activation-ready' form [6]. It 
is of interest that P R G B is expressed in the liver, and most 
prominently in cancer cells [7]. The regulation of these genes, 
however, has not yet been explored. 
In order to understand the expression of P R G A and 
P R G B , it is essential to study the transcriptional regulation 
of these genes. In the present report, the sequences of the 5'-
flanking regions of P R G A and P R G B are established and 
their transcriptional activity is demonstrated to be largely de-
pendent on a region surrounding the transcription initiation 
site of P L G [8]. 
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2. Materials and methods 
2.1. Sequence analysis 
Genomic clones containing the 5'-flanking region of PRGA and 
PRGB were obtained by screening the human fibroblast library, as 
reported previously [4,5]. Genomic DNA inserts were excised from the 
phage clones with EcoRI, and then subcloned into plasmid vector 
pUC18. The excised fragments were also subcloned into M13mpl8 
or mpl9, and sequenced by the dideoxy termination method [9] em-
ploying [35S]dATP and buffer gradient gels [10]. 
2.2. Construction of CAT vector 
Each 1.1 kb fragment of the 5'-flanking regions of PRGA and 
PRGB was isolated from the subcloned vectors, and ligated into pro-
moterless pCAT-Basic and -Enhancer vectors (Promega, Madison, 
WI) in front of the chloramphenicol acetyltransferase (CAT) gene. 
The resultant plasmids contained the 5'-flanking sequences of 
PRGA and PRGB spanning from positions —910 to +153 relative 
to the transcription start site in PLG [8]. Fragments spanning from 
positions -698 and -283 to +153 of either PRGA or PRGB were 
obtained by digestion with Xba\ and Hindlll, respectively, and reli-
gation. The resulting DNA fragments were released and cloned into 
the pCAT vectors. The orientation and sequence of these constructs 
were verified by digestion with several restriction enzymes and the 
dideoxy termination method. Plasmids were prepared by double ultra-
centrifugation in cesium chloride density gradient. 
The CAT plasmids containing the PLG genes constructed in a 
previous study [11] were also used as references. 
2.3. Cell culture and transfections 
HepG2 cells, a human hepatoma cell line (Japanese Cancer Re-
search Resources Bank, Tokyo), were cultured in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine serum and anti-
biotics (penicillin, streptomycin, and neomycin). 10 ug of test plasmids 
and 5 ug of pSV-(3-galactosidase plasmid (Promega) as an internal 
control were cotransfected into cultured cells by the calcium phos-
phate precipitation method. Both pCAT-Basic and -Control vectors 
were also employed as negative and positive controls, respectively. 
The cells were incubated for 5 h and exposed to 15% (v/v) glycerol 
in HEPES-buffered saline for 2 min. After being cultured for 48 h, the 
cells were harvested for analysis. Each transfection was repeated at 
least four times and the average results are presented. 
These experiments were also carried out employing human embry-
onic kidney 293 cells and baby hamster kidney (BHK) cells. 
2.4. CAT and $-galactosidase assay 
CAT activity was measured by the standard method [12], and p-
galactosidase activity by the colorimetric method [13]. CAT activity 
was normalized to (5-galactosidase activity to correct for differences in 
transfection efficiency and cell number. 
3. Results and discussion 
3.1. 5'-Flanking sequences of PRGA and PRGB 
Sequences of more than 1000 bp of the 5'-flanking and 5'-
untranslated regions of P R G A and P R G B were established in 
the present study and were compared to each other (Fig. 1). 
The sequences of P R G A and P R G B are 94.5% identical to 
that of P L G . P R G A and P R G B differ in sequence from each 
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P R G A GAATTCCGCAG-ACAT - 8 9 6 
*********** **** 
PLG GAATTCCGCAGGACAT -901 
******* ****** * 
PRGB GAATTCCACAGGACGT -896 
PRGA TCCACCCAAGACCACTGGGCTCCCACCTCTACTCTTTTGCCAGTTAATGAATAGGCAGGAATTTCACTGCCTGGAAAGAGGAACAATGCTTTCTGGTCCT -796 
************** ************************************************************************************* 
PLG TCCACCCAAGACCATTGGGCTCCCACCTCTACTCTTTTGCCAGTTAATGAATAGGCAGGAATTTCACTGCCTGGAAAGAGGAACAATGCTTTCTGGTCCT - 8 01 
**************************************************************************************************** 
PRGB TCCACCCAAGACCATTGGGCTCCCACCTCTACTCTTTTGCCAGTTAATGAATAGGCAGGAATTTCACTGCCTGGAAAGAGGAACAATGCTTTCTGGTCCT - 7 9 6 
CACCC CCAAT IL-6 CCAAT 
PRGA TATTTCACATCTGACATAGAGAGGTCAATTGATTTATTCCTAAATATCTTTGAACACTAAAATAGAAGTTTTACAGCATATATACTACCTGGTTGCTCTA -6 9 6 
************ * ************************************************************************************* 
PLG TATTTCACATCTAAAATAGAGAGGTCAATTGATTTATTCCTAAATATCTTTGAACACTAAAATAGAAGTTTTACAGCATATATACTACCTGGTTGCTCTA - 7 01 
************************************** ************************************ ************************ 
PRGB TATTTCACATCTAAAATAGAGAGGTCAATTGATTTATTGCTAAATATCTTTGAACACTAAAATAGAAGTTTTACAACATATATACTACCTGGTTGCTCTA - 6 9 6 
LF/A1 CCAAT NF IL-6 TATA TATA 
PRGA GACTTAAGCCAGGGAAAAGTACAGATTCAACATTTAAAATTGAGATAGACGCTTTCCACTTAATGCTACCAGTCTTGCTTTATTTCATGAGAATGAGAAT. - 5 9 6 **************************************************************************************************** 
PLG GACTTAAGCCAGGGAAAAGTACAGATTCAACATTTAAAATTGAGATAGACGCTTTCCACTTAATGCTACCAGTCTTGCTTTATTTCATGAGAATGAGAAT_ - 6 01 
************************************************************** ************************************* 
PRGB GACTTAAGCCAGGGAAAAGTACAGATTCAACATTTAAAATTGAGATAGACGCTTTCCACTTAGTGCTACCAGTCTTGCTTTATTTCATGAGAATGAGAAT. - 5 9 6 
PRGA ATAATAATATGGCATACGTTCATTTGGGGGAAAGATTGATGTCTTATAA TTTATAATTACAGAAAACATGTGAGTTCACTGGGAATAAATAAATT - 5 01 
************************************************* ********************************************** 
PLG ATAATAATATGGCATACGTTCATTTGGGGGAAAGATTGATGTCTTATAACATAATTTATAATTACAGAAAACATGTGAGTTCACTGGGAATAAATAAATT - 5 01 
*********** ************************************* **************************************** ***** 
PRGB ATAATAATATGCCATACGTTCATTTGGGGGAAAGATTGATGTCTTATAA TTTATAATTACAGAAAACATGTGAGTTCACTGGGAATAAAGAAATT - 5 01 
TATA CCAAT TATA TATA NF IL-6 LF/A1 IL-6 
PRGA TTGAAGATAATAAGATACTTTCACTTATGTCGTAATTTCTATGTCATTTGATGTAGGATGTGGAGATATTAACATTTATACCTAACTTAAGTTTGTCATC -401 ******************************* ****************** ********************** **** ******** ************ 
PLG TTGAAGATAATAAGATACTTTCACTTATGTCATAATTTCTATGTCATTTGGTGTAGGATGTAGAGATATTAACGTTTACACCTAACTCAAGTTTGTCATC -401 ******************************* ***************************************** ************* ************ 
PRGB TTGAAGATAATAAGATACTTTCACTTATGTCGTAATTTCTATGTCATTTGGTGTAGGATGTGGAGATATTAACATTTACACCTAACTTAAGTTTGTCATC -401 
AP-1 
PRGA CAAGACCTGAAAGGGTTTTGTCTATCAGCTGCACCCCTGGGTAGCGACACAACCTTGGGGAAGGCCTCAACCCCATCCCTCGTACAGCAGGAATGAGAAC -301 ******************************************* ************************ ****************************** 
PLG TAAGACCTGAAAGGGTTTTGTCTATCAGCTGCACCCCTGGGTAGAGACACAACCTTGGGGAAGGCCTCAGCCCCATCCCTCGTACAGCAGGAATGAGAAC -301 
* ***************************************** ******************************************************* 
PRGB CAGGACCTGAAAGGGTTTTGTCTATCAGCTGCACCCCTGGGTAGCGACACAACCTTGGGGAAGGCCTCAGCCCCATCCCTCGTACAGCAGGAATGAGAAC - 3 01 
AP-2 NF IL-6 AP-2 
PRGA AGCACTGCCTGTTGGGAAGCTTGAGGGAGGCTATGGACGTGCAGTGCTTGGCAGAGGGTCTCGTCATGGAAGGTTCCAGCAAATGTGAGATACTTTTATG - 2 01 *** **************************************** ********** ******************************************** 
PLG AGCCCTGCCTGTTGGGAAGCTTGAGGGAGGCTATGGACGTGCAGCGCTTGGCAGAAGGTCTCGTCATGGAAGGTTCCAGCAAATGTGAGATACTTTTATG - 2 01 
*** *************************************************** ***************************************** ** 
PRGB AGCACTGCCTGTTGGGAAGCTTGAGGGAGGCTATGGACGTGCAGCGCTTGGCAGAGGGTCTCGTCATGGAAGGTTCCAGCAAATGTGAGATACTTTTCTG -201 
PRGA AGTTCATTTTCTCCAAAAGAAAGGGAATAAAAGAAGAGGGGAGGAAATAAGACTAATTGTGAGAGATGAAGTACAAGGGTGAGGGAAGGAGTAAGGAGAC -101 
* **************************** **************************** ******* ********************** ********* 
PLG ATTTCATTTTCTCCAAAAGAAAGGGAATAAGAGAAGAGGGGAGGAAATAAGACTAATTGCGAGAGATAAAGTACAAGGGTGAGGGAAGGAATAAGGAGAC -101 ****************************** **************************** **************** ************* ********* 
PRGB ATTTCATTTTCTCCAAAAGAAAGGGAATAAAAGAAGAGGGGAGGAAATAAGACTAATTGTGAGAGATAAAGTACAAAGGTGAGGGAAGGAGTAAGGAGAC -101 
CCAAT C/EBP GATA NF IL-6 
TGTAA 
PRGA ATGAAGGCAGCATGGAGCAGCTGAGGGGGGAGATTGCTTTCACCACTTCCCAGCATCTATTGCAGATTCCACCCTCAATCATTTTGTAAGGACCCTTTAT -1 
**** ****** ********* ******************************************************** ************** ****** 
PLG ATGACGGCAGCGTGGAGCAGCCGAGGGGGGAGATTGCTTTCACCACTTCCCAGCATCTATTGCAGATTCCACCCTCAAACATTTTGTAAGGACTCTTTAT -1 
**** ****** ********* ******************************************************** ************** ****** 
PRGB ATGAAGGCAGCATGGAGCAGCTGAGGGGGGAGATT^TTTCACCACTTCCCAGCATCTATTGCAGATTCCACCCTCAATCATTTTGTAAGGACCCTTTAT -1 
C R E B C/EBP NF IL-6 C/EBP CACCC CCAAT DBS' NF~IL-6 
PRGA TCAAGGTTATGTTTGAACCCTGCTGAGCCAGTGGCGTGGGTGTCTGAGAGAATCATTACCTTAATTTGACTATCTGGTCTGTGGATGCGTTTACTCTCAT 100 ******* * ************************* ***** **************** ******************* ********************* 
PLG TCAAGGTAACGTTTGAACCCTGCTGAGCCAGTGGCATGGGTCTCTGAGAGAATCATTAACTTAATTTGACTATCTGGTTTGTGGATGCGTTTACTCTCAT 100 
******* ************************* ***** ************************************ ********************* 
PRGB TCAAGGTCGTGTTTGAACCCTGCTGAGCCAGTGGCGTGGGTGTCTGAGAGAATCATTAACTTAATTTGACTATCTGGTCTGTGGATGCGTTTACTCTCAT 100 
+ , LF/A1 AP-1 HNF-1 AP-1 
PRGA GTAAGTCAACAACATCCTGGGATTGGGACACACTTTCTGGGCACTGCTGGCCAGTCCCAAA ATG GAA CAT AAG GAA GTG GTT CTT CTA CTT 
***************************** ******************************* *** *** *** *** *** *** *** *** *** *** 
PLG GTAAGTCAACAACATCCTGGGATTGGGACCCACTTTCTGGGCACTGCTGGCCAGTCCCAAA ATG GAA CAT AAG GAA GTG GTT CTT CTA CTT 
***************************** ******************************* *** *** *** *** *** *** *** *** *** *** 
PRGB GTAAGTCAACAACATCCTGGGATTGGGACACACTTTCTGGGCACTGCTGGCCAGTCCCAAA ATG GAA CAT AAG GAA GTG GTT CTT CTA CTT 
AP-1 IL-6 M E H K E V V L L L 
Fig. 1. Nucleotide sequences of the 5'-flanking regions of PLG, PRGA and PRGB. Nucleotide numbers are shown in the right margin. Aster-
isks show nucleotides identical to those of the PLG gene. Consensus sequences for transcription regulatory elements are underlined and la-
beled. 
other by 1-2%. Both genes are missing 5 nucleotides (from identical to those in PRGA and PRGB. This spatial arrange-
—551 to —547 bp) in the PLG gene. ment was also assigned in PRGA and PRGB. Although three 
The sequences surrounding the transcription start site TATA boxes were present between —600 and —550 bp in all 
(numbered +1) and translation initiation site of PLG [8] are three genes, there was no canonical TATA sequence around 
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Fig. 2. Transient expression of CAT activity of reference constructs 
transfected into HepG2 (top), 293 cells (middle), and BHK cells 
(bottom). The CAT activity of the control SV40 early promoter vec-
tor was defined as 100% in HepG2 cells to normalize the CAT ac-
tivity of other constructs including the original 1.1 kb PLG plasmid 
and the promoterless CAT vector. 
the transcription initiation site. Instead, these genes have a 
TATA-like sequence, TGTAA, at position —16 (Fig. 2). 
This sequence corresponds exactly to the TATAA box of 
the homologous apolipoprotein (a) gene [14,15], which is lo-
cated 31 bp upstream from its transcription start site [16]. 
Accordingly, the TGTAA sequence is very likely involved in 
the expression of the TATA-less promoter in these three 
genes. 
Various consensus sequences for binding sites of transcrip-
tion factors were found by a computer-assisted search em-
ploying a directory [17]; these include sites for AP-1, C/ 
EBP, CREB, HNF-1, LF/A-1, NF-IL6, etc. (Fig. 1). Since 
PLG and PRGB are synthesized in the liver, it was of interest 
to examine the related genes for consensus sequences of liver-
specific and liver-enriched transcription factors. A sequence 
homologous to the HNF-1 site (GTTAATNATTAAC [17]) 
was identified in PLG and PRGB, while PRGA lacks this 
site because of a single mismatch at position +59. There 
were two sites of the consensus sequence for C/EBP 
(GTGGT/AT/AT/AG or ATTGC [17]) in PRGA and 
PRGB which were common among all three genes, while 
one at —145 bp exists only in PLG. There were also three 
sites for LF/A-1 (TGG/AA/CCC [18]) in all three genes, and a 
DBP site (TGATTTTGT [17]) in PRGA and PRGB. Among 
these sites, those for C/EBP, CCA AT, DBP, LF/A-1, HNF-1, 
and AP-1 were located within 50 bp from the transcription 
initiation site of PLG [8,11]. It is common for a transcription 
initiation site to be surrounded by many regulatory elements. 
It is of particular interest that three IL-6 responsive ele-
ments (or acute-phase response factor, APRF, sites) 
(CTGGG/AA [19,20]) are also located in the 5'-flanking re-
gions of these genes. IL-6 stimulation of HepG2 cells trans-
fected with a CAT construct for PLG resulted in a 2.5-fold 
increase in the reporter expression [11]. Thus, these three 
genes might be up-regulated by IL-6 during the acute-phase 
response. 
PRGA and PRGB have three sites for a ubiquitous tran-
scription factor AP-1 (TGAG/CTC/AA [17]), while PLG has 
four, due to one nucleotide difference at position —413. 
3.2. Promoter activity of the homologous genes 
To examine whether PRGA and PRGB are functionally 
active, each 1.1 kb DNA fragment carrying the 5'-flanking 
region of one of the three genes was linked to a promoterless 
CAT reporter plasmid. Low but detectable levels of CAT 
activity were produced in HepG2 cells, e.g. a plasmid contain-
ing the 1.1 kb fragment of PLG had CAT activity about 9-
Fig. 3. CAT activity by deletion constructs transfected into HepG2 cells. Left: A series of PRGA- or PRGB-CAT fusion constructs containing 
varying lengths of their 5'-flanking sequences. Right: CAT activity expressed by deletion constructs. The CAT activity of the original 1.1 kb 
PLG vector was arbitrarily defined as 100% in HepG2 cells and used as a reference to normalize the CAT activity of other genes. 
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Fig. 4. Schematic comparison of the putative transcription regulatory sites present in PRGA and PRGB and those of PLG. Each element is la-
beled according to its corresponding transcription factor: 1, HNF-1; 6, IL-6; A, AP-1; C, CCAAT; D, DBP; E, C/EBP; G, GATA; L, LF/A-
1; R, CREB. 
fold higher than that obtained with a reference promoterless 
CAT vector. When presented as a percentage of the control 
SV40 early promoter gene (100%), the relative promoter ac-
tivity was 22.0% for PLG, 65.3% for PRGA and 109% for 
PRGB (Fig. 2). Thus, the relative promoter activity of these 
two highly homologous genes was much higher than that of 
PLG. Similar but somewhat different results were reported by 
other investigators [16], probably due to their employing a 1.3 
kb fragment containing all of exon I and about 150 bp of 
intron A. Since the coding sequence of exon I was included 
in their construct, the difference in expression activity might 
be attributable to translational efficiency rather than tran-
scriptional efficiency, as reported in the apolipoprotein (a) 
gene [21]. 
Essentially no CAT activity was observed with the 1.1 kb 
fragments in 293 cells nor in BHK cells. These results indicate 
that the 1.1 kb 5'-flanking sequence is sufficient to direct basal 
liver-specific gene expression of these genes. 
3.3. Deletion analysis of CAT vectors 
Stepwise deletion constructs were generated from the 1.1 kb 
fragments of the three genes, and tested for activity in HepG2 
cells (Fig. 3). A deletion from —910 to —698 bp resulted in a 
2.5-fold increase in activity in PRGA and a 1.9-fold increase 
in PRGB, while a deletion from —915 to —703 bp caused a 
1.8-fold increase in PLG [11]. These results suggest the pres-
ence of a cis-acting negative element in this region of each 
gene. The possible silencer sequence(s) is, however, not yet 
clear. 
A further deletion from —698 to —283 bp caused a 2.1-fold 
reduction in activity in both PRGA and PRGB, while a dele-
tion from —703 to —283 bp resulted in a 3.7-fold increase in 
PLG. These results indicate that an additional negative ele-
ment is present in PLG and that there is a positive element in 
this region of PRGA and PRGB. As described above, PLG 
has a unique AP-1 site at -418 bp, while PRGA and PRGB 
lack this site (Figs. 1 and 4). Since all the remaining consensus 
sequences are common in these three genes, it is likely that the 
putative AP-1 site in PLG acts as a silencer [22]. 
Since the sequence from —283 to +153 bp supported sig-
nificant transcriptional activity, it is concluded that the pro-
moter is present in this region, and the sequences close to the 
transcription initiation site play an essential role in the regu-
lation of these genes. 
Expression of these genes may be modulated under partic-
ular conditions, such as malignant transformation. Indeed, in 
contrast to mRNA for PRGA, mRNA for PRGB has been 
detected in larger amounts in several cancer cells than in the 
corresponding normal cells ([7]; Tateno and Ichinose, unpub-
lished data). The preactivation peptide domain of PLG plays 
an essential role in conversion of the 'activation-resistant' 
conformation to the 'activation-ready' form [6]. Accordingly, 
increased levels of the gene product of PRGB composed of 
the preactivation peptide domain alone may affect the activa-
tion of PLG to plasmin, and may play a role in invasion and 
metastasis of cancer cells, such as the extracellular matrix 
destruction [2,3]. This assumption is analogous to the fact 
that a 38 kDa fragment of PLG named angiostatin, but not 
intact PLG, potently inhibits neovascularization, growth of 
tumors and their metastases [23]. 
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